The regulatory requirements in the GMP environment have changed noticeably in recent years. In 2025, it is clearer than ever that it is no longer enough to formally fulfill requirements. Authorities expect comprehensible decisions, stable processes and quality that is actually practiced in day-to-day work. For many companies, this means a fundamental organizational, technical and cultural rethink.
GMP is increasingly understood as an integrated system in which processes, people, data and technology are closely interlinked. Individual measures or isolated corrections are not enough to remain audit-proof in the long term.
From documentation to active GMP compliance
Inspections and audits are increasingly focusing on how quality systems actually function in day-to-day business. Deviation management, change control and CAPA processes are no longer viewed in isolation, but in the context of responsibilities, interfaces, escalation paths and decision-making logic.
2025 has shown that inspectors are increasingly questioning who makes decisions, on what professional basis they are made and how consistently they are implemented. Processes that appear conclusive on paper but are interpreted or applied differently in everyday life quickly come into focus.
A key learning: Consistency is a decisive GMP factor. Differences between shifts, locations or areas of responsibility are increasingly seen as a systemic risk. Especially if they are not recognized, evaluated or justified.
CAPA, change control and deviations considered in context
Current FDA warning letters make it clear that a purely formal processing of deviations and CAPA measures is no longer accepted. The FDA is particularly critical of so-called “testing to compliance”, in which tests are repeated without identifying the actual cause of a problem and eliminating it sustainably.
Instead, the FDA expects robust root cause analyses with a broader perspective: affected and adjacent batches, comparable products, shared facilities and historical trends must be systematically included. A comprehensible effectiveness test of the CAPA measures is also required.
Prompt and visible action is required when risks are high or unacceptable. Delays – even if they are corrected later – weaken confidence in the quality system from the FDA’s perspective. At the same time, there is a greater focus on the responsibility of the quality unit and management: effective CAPA requires active quality oversight, continuous trend analyses and clear decision-making processes.
Data integrity remains a critical checkpoint
Data integrity continues to be one of the most sensitive issues in the GMP environment – and 2025 has further intensified this development. Authorities are paying more attention to complete audit trails, consistent data flows, clear role and access concepts and the handling of exceptions and manual interventions.
It is striking that data integrity is increasingly understood not only as an IT issue, but as a cross-organizational task. Training, awareness and leadership play just as big a role as technical controls.
Technology, processes and quality units in interaction
Technical weaknesses – for example in system qualification, maintenance, cleaning or monitoring – continue to lead to frequent complaints. However, it is less and less the individual defect that is decisive, but rather the question of how systematically companies deal with such issues.
2025, it became clear that authorities are evaluating more closely whether processes are understood, monitored and continuously improved or whether they are merely reacting to deviations. A reactive approach is increasingly considered insufficient.
At the same time, the role of the quality unit is becoming more central. Quality units are no longer seen primarily as an approval office, but as an
Lessons learned 2025: Recurring patterns from audits
Across many audits, a number of overarching findings can be identified for 2025:
- Unclear responsibilities are a frequent starting point for GMP deviations
- Decisions without documented professional justification are increasingly being questioned
- Training alone is not enough, application and understanding count
- Quality systems must function as a whole, not just in individual modules
Companies that recognize and address these patterns at an early stage are in a much better position than those that only react selectively.
Outlook: GMP will be even more digital, risk-based and networked in 2026
Looking ahead to 2026, it can be assumed that these developments will continue to intensify. GMP practice is clearly moving in this direction:
- more integrated digital quality systems
- Data-based trend analyses and key figures
- Predictive quality assurance instead of pure error correction
Risk-based approaches are finally no longer a “nice to have”, but the regulatory standard. At the same time, the requirements for transparency, traceability and system understanding are increasing, especially for complex manufacturing processes, biologics and novel therapies.
Companies that take a holistic approach to their GMP organization today not only create audit security, but also long-term stability in an increasingly complex regulatory environment.
How the Experts Institute supports you
We support companies throughout the entire GMP life cycle: from GMP assessments and audit preparations to hands-on support in projects, interim management and practical training for specialists and managers. Our focus is always on practicable solutions, regulatory safety and quality that works in everyday life.
Our claim: GMP compliance that doesn’t just exist on paper, but withstands audits and strengthens processes in the long term. Contact us if you want to future-proof your GMP organization. Get ahead and in touch with us – info@expertsinstitut.de
Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut
